The pediatric neurologist at Johns Hopkins Medicine provided commentary on the steps needed to improve treatment optimization in SMA, and the unanswered questions regarding the key biology of the disease.
Episode 3 of the AUPN Leadership Minute features Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas; and Mehmood Rashid, MD, of University of Toledo. [WATCH TIME: 4 minutes]
The professor of neurology at Vanderbilt University Medical Center discussed advocating for reinstating personalized resources, expanding genetic testing, and improving transitional care in muscular dystrophy. [WATCH TIME: 5 minutes]
The CEO and cofounder of Amprion spoke about additional diagnostic uses of the αSyn seed amplification assay and its validation in the Parkinson's Progression Markers Initiative study at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
The associate professor of neurology at The Ohio State University Wexner Medical Center provided insight on research assessing the use of a developed artificial intelligence/machine learning tool for automated stroke scale calculation. [WATCH TIME: 6 minutes]
The director of clinical outcomes and research development in neurology at Stanford University spoke about the paradigm shift in neuromuscular therapy interventions at the 2023 MDA conference. [WATCH TIME: 5 minutes]
Closing thoughts on advice to community neurologists treating spinal muscular atrophy (SMA).
The director of the center for gene therapy at Nationwide Children's Hospital talked about the challenges and opportunities of gene therapies for neuromuscular diseases at the 2023 MDA conference. [WATCH TIME: 4 minutes]
The headache fellow at Cleveland Clinic outlined the design and reasoning for a new study assessing nerve blocks to treat COVID-19 headache.
The clinical research associate at the University of Texas Health Science Center at San Antonio discussed a study that explores the relationship between cognitive function and gut microbiome structure in middle-aged adults from the Framingham Heart Study cohort. [WATCH TIME: 4 minutes]
At the 2022 AES annual meeting, the associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital talked about seizure frequency and insomnia. [WATCH TIME: 2 minutes]
The chief scientific officer of AMO Pharma discussed results from a recent clinical trial evaluating the safety and efficacy impact of AMO-02 on children and adolescents with congenital myotonic dystrophy. [WATCH TIME: 6 minutes]
The neurosurgeon at Allegheny Health Network detailed the potential for robotics in neurosurgery over the coming years, and the vast improvements in comfortability during these procedures. [WATCH TIME: 3 minutes]
The director of the neuromuscular diseases division at the University of Washington discussed findings from a new post hoc analysis presented at AANEM 2023 that showed that zilucoplan treatment significantly reduced fatigue in patients with myasthenia gravis. [WATCH TIME: 6 minutes]
In this episode of MEDcast, expert geriatric psychiatrists explore the urgent need for effective diagnostic methods that can detect Alzheimer’s disease at an early stage. We will discuss blood-based biomarkers and other advancements that can help screen Alzheimer’s disease non-invasively and early in the disease course.
The vice president of Innovation and New Technologies at Grifols provided perspective on the interim phase 2 findings of ABvac40, a vaccine in development for patients with Alzheimer disease. [WATCH TIME: 3 minutes]
Tanuja Chitnis, MD and Lauren B. Krupp, MD give insight into the future of pediatric multiple sclerosis by discussing unmet needs and advice for community neurologists.
For women, the decision to opt for an unconventional career path can be inspired by conflicting responsibilities and balancing life with work. But, as Sana Syed, MD, MPH, explains, following your passion is still an achievable dream despite these challenges.
Charlene Gamaldo, MD, discusses patient criteria for selecting a dual orexin receptor agonist (DORA) for insomnia treatment.
The effect of gaslighting on patients can result in serious harms, and although it is potentially common in the MS care continuum, whether it is deliberate or an institutional problem, it must be called out by providers.
The scientific researcher and clinical manager, Icahn School of Medicine at Mount Sinai, spoke about the clinical models used to predict seizures in poststroke patients. [WATCH TIME: 4 minutes]
The senior vice president of medical and clinical affairs for Avadel Pharmaceuticals provided commentary on recently published research supporting once-nightly sodium oxybate (Lumryz) in narcolepsy regardless of the subtype. [WATCH TIME: 5 minutes]
The director and founder of the Sleep Centers of Middle Tennessee discussed trends in positive airway pressure adherence that his center’s research has revealed.
The professor of neurology at Harvard Medical School spoke at the 2023 ISC Conference about highlights from the STROKE-AF study after a 3-year follow-up. [WATCH TIME: 5 minutes]
The global head of medical affairs-neurology at Janssen Pharmaceutical provided background on the need for real-world studies and how they can accurately portray a disease community.
Mary Anne Meskis; Tracy Dixon-Salazar, PhD; Kelly Knupp, MD; and Joseph E. Sullivan, MD, provide advice for physicians treating patients with Dravet syndrome or LGS.
The chief executive officer of Cognixion talked about the Cognixion ONE Axon, a wireless, wearable brain-computer interface that combines EEG technology with an augmented reality headset for patients with neurodegenerative diseases. [WATCH TIME: 4 minutes]
The headache specialist at the Hartford Healthcare Headache Center discussed findings from a study that revealed altered retinal vasculature in individuals with migraine with aura, indicating potential retinal biomarkers for disease progression. [WATCH TIME: 4 minutes]
The associate professor, department of medicine, division of neurology, Institute of Medical Science, University of Toronto, shared his thoughts on potential therapies and expanding care options for sleep disorders in 2024. [WATCH TIME: 5 minutes]